You are currently viewing a beta version of our website. If you spot anything unusual, kindly let us know.
Altmetrics
Downloads
88
Views
31
Comments
0
A peer-reviewed article of this preprint also exists.
All patientsN = 59 | No MACE or deathN = 39 | MACE or deathN = 20 | p-value | |
---|---|---|---|---|
Galectin-3 at site: | ||||
Aortic root (Q1, Q3), ng/ml | 9.2 (6.8-12.1) | 8.2 (5.9-9.9) | 13.9 (10.8-16.2) | <0.001 |
Femoral/radial artery + SD, ng/ml | 9.72 ± 3.62 | 8.53 ± 3.46 | 11.55 ± 3.15 | 0.005 |
Coronary sinus + SD, ng/ml | 9.74 ± 3.76 | 8.43 ± 2.57 | 12.56 ± 4.40 | 0.001 |
Cubital vein + SD, ng/ml | 9.31 ± 3.35 | 8.05 ± 2.21 | 12.06 ± 3.80 | <0.001 |
Age + SD, years | 65 ± 9 | 63 ± 8 | 69 ± 10 | 0.013 |
Gender (male), n (%) | 42 (71) | 32 (78.0%) | 9 (50.0%) | 0.063 |
BMI + SD, kg/m2 | 27.8 + 3.52 | 27.8 ± 3.4 | 27.8 ± 3.9 | 0.960 |
Smoking, n (%) | 18 (31) | 14 (34) | 4 (22) | 0.540 |
Diabetes mellitus, n (%) | 20 (34) | 14 (70) | 6 (30) | 0.999 |
CVI, n (%) | 3 (5) | 2 (5) | 1 (6) | 0.999 |
Hypertension, n (%) | 38 (64) | 24 (58) | 14 (78) | 0.238 |
Hyperlipoproteinemia, n (%) | 17 (29) | 11 (27) | 6 (33) | 0.756 |
STEMI, n (%) | 38 (64) | 23 (56) | 15 (83) | 0.044 |
Anterior MI, n (%) | 26 (44) | 16 (41) | 10 (50) | 0.239 |
Inferior MI, n (%) | 33 (56) | 23 (59) | 10 (50) | 0.969 |
NSTEMI, n (%) | 21 (36) | 16 (41) | 5 (25) | 0.044 |
Time from pain onset (Q1, Q3), hours | 10.0 (4.0-18.0) | 9.5 (4.0-20.0) | 8.5 (3.5-15.5) | 0.882 |
AV block, n (%) | 3 (5) | 0 (0) | 3 (17) | 0.025 |
VT/VF, n (%) | 7 (12) | 5 (12) | 2 (11) | 0.999 |
AF, n (%) | 5 (8) | 2 (5) | 3 (17) | 0.160 |
Systolic BP + SD, mmHg | 130 ± 28 | 137 ± 27 | 115 ± 26 | 0.005 |
Diastolic BP + SD, mmHg | 75 ± 17 | 79 ± 17 | 68 ± 15 | 0.023 |
HR + SD, bpm | 74 ± 14 | 76 ± 11 | 70 ± 21 | 0.272 |
Urea (Q1, Q3), mmol/l | 6.3 (4.9-8.5) | 5.8 (4.6-6.9) | 9.6 (7.4-13.3) | 0.003 |
Creatinine (Q1, Q3), μmol/l | 87.0 (78.0-100.0) | 86.0 (77.0-93.8) | 115.5 (79.8-167.8) | 0.044 |
Creatinine clearance + SD, ml/min | 83.41 ± 27.17 | 91.79 ± 21.29 | 64.32 ± 29.95 | <0.001 |
Cholesterol + SD, mmol/l | 5.68 ± 1.32 | 5.88 ± 1.19 | 5.22 ± 1.51 | 0.081 |
HDL + SD, mmol/l | 1.13 ± 0.26 | 1.12 ± 0.21 | 1.15 ± 0.35 | 0.742 |
LDL + SD, mmol/l | 3.66 ± 1.15 | 3.86 ± 1.02 | 3.19 ± 1.33 | 0.042 |
Triglycerides (Q1, Q3), mmol/l | 1.7 (1.1-2.3)) | 1.7 (1.2-2.5) | 1.3 (1.0-2.0) | 0.303 |
CK-MB (Q1, Q3), U/l | 24.0 (15.0-52.0) | 24.0 (16.2-54.0) | 25.0 (12.2-35.8) | 0.987 |
CRP (Q1, Q3), mg/l | 5.0 (1.5-10.6) | 4.2 (1.2-10.1) | 5.2 (2.7-33.0) | 0.278 |
Troponin T (Q1, Q3), ng/ml | 1.2 (0.2-7.3) | 1.1 (0.3-5.8) | 2.6 (0.1-5.2) | 0.593 |
Pro-BNP (Q1, Q3), pg/ml | 459.5 (239.7-2182.7) | 372.5 (180.2-1979.5) | 2250.0 (275.2-6492.8) | 0.004 |
Glycaemia (Q1, Q3), mmol/l | 6.2 (5.3-8.4) | 6.0 (5.3-7.0) | 8.2 (5.0-12.6) | 0.040 |
Potassium (Q1, Q3), mmol/l | 4.3 (4.0-4.6) | 4.2 (3.9-4.7) | 4.5 (4.1-4.7) | 0.281 |
Sodium (Q1, Q3), mmol/l | 139.0 (137.0-141.0) | 139.0 (137.2-141.0) | 139.5 (136.0-141.2) | 0.680 |
RBC + SD, x1012/l | 4.61 ± 0.56 | 4.73 ± 0.51 | 4.30 ± 0.58 | 0.007 |
Haemoglobin + SD, g/l | 137.43 ± 18.99 | 144.44 ± 14.62 | 120.53 ± 17.91 | <0.001 |
Leukocyte count (Q1, Q3), x109/l | 9.6 (8.6-12.0) | 9.4 (8.4-11.6) | 10.1 (7.4-12.9) | 0.657 |
Platelet count + SD, x109/l | 238.03 ± 65.60 | 232.73 ± 55.37 | 250.822 ± 80.62 | 0.406 |
LVEF + SD, % | 52 ± 5 | 53 ± 5 | 50 ± 6 | 0.157 |
EDV + SD, mm | 77.62 ± 22.65 | 76.82 ± 21.73 | 79.53 ± 25.33 | 0.683 |
ESV + SD, mm | 38.25 ± 13.38 | 38.8 (10.2-45.8) | 38.0 (31.5-45.8) | 0.392 |
E/A ratio (Q1, Q3) | 0.7 (0.6-0.8) | 0.7 (0.6-0.8) | 0.7 (0.6-1.0) | 0.925 |
E/E` ratio (Q1, Q3) | 7.9 (6.6-10.0) | 7.8 (6.5-9.7) | 8.0 (6.6-12.2) | 0.263 |
LA + SD, mm | 37.72 ± 4.93 | 38.20 ± 4.95 | 36.59 ± 4.84 | 0.262 |
Number of coronary lesions + SD | 1.67 + 0.87 | 1.68 ± 0.82 | 1.65 ± 1.00 | 0.887 |
1-vessel CAD, n (%) | 11 (19) | 8 (21) | 3 (15) | 0.869 |
2-vessel CAD, n (%) | 20 (34) | 15 (38) | 5 (25) | 0.601 |
3-vessel CAD, n (%) | 28 (47) | 16 (41) | 12 (60) | 0.029 |
Furosemide, n (%) | 18 (31) | 9 (22) | 9 (53) | 0.030 |
Spironolactone, n (%) | 10 (17) | 5 (12) | 5 (29) | 0.139 |
ACE inhibitors, n (%) | 42 (71) | 32 (78) | 10 (59) | 0.197 |
Beta-blockers, n (%) | 43 (73) | 33 (80) | 10 (59) | 0.107 |
Calcium channel antagonists, n (%) | 7 (12) | 3 (7) | 4 (23) | 0.178 |
Amiodarone, n (%) | 13 (22) | 8 (19) | 5 (29) | 0.494 |
DAPT, n (%) | 53 (90) | 39 (95) | 14 (82) | 0.144 |
Ticagrelor, n (%) | 33 (56) | 26 (63) | 7 (41) | 0.151 |
Trimetazidine, n (%) | 25 (42) | 18 (44) | 7 (41) | 0.999 |
Statins, n (%) | 54 (92) | 39 (95) | 15 (88) | 0.573 |
UFH/LMWH, n (%) | 55 (93) | 40 (98) | 15 (94) | 0.999 |
Event | n (%) |
---|---|
MACE, n (%) | 20 (100) |
Death, n (%) | 5 (25) |
Re-AMI, n (%) | 1 (5) |
Cerebrovascular insult, n (%) | 4 (20) |
Re-hospitalization due to heart failure, n (%) | 5 (25) |
Re-hospitalization due to malignant arrhythmias, n (%) | 5 (25) |
Univariate analysis | OR (95%CI) | p-value | R2 | HL test p-value |
---|---|---|---|---|
Galectin-3 at site: | ||||
Aortic root | 1.277 (1.076-1.517) | 0.005 | 0.255 | 0.581 |
Femoral/radial artery | 1.309 (1.068-1.604) | 0.009 | 0.224 | 0.556 |
Coronary sinus | 1.422 (1.155-1.750) | 0.001 | 0.342 | 0.48695 |
Cubital vein | 1.566 (1.225-2.000) | <0.001 | 0.405 | 0.454 |
Age (years) | 1.089 (1.014-1.169) | 0.018 | 0.145 | 0.289 |
Gender (male) | 0.281 (0.086-0.918) | 0.036 | 0.103 | 0.301 |
STEMI | 3.913 (0.980-15.625) | 0.053 | 0.101 | 0.300 |
NSTEMI | 0.256 (0.064-1.020) | 0.053 | 0.101 | 0.300 |
3-vessel CAD, n (%) | 3.375 (1.110-12.669) | 0.033 | 0.115 | 0.256 |
Systolic BP (mmHg) | 0.968 (0.945-0.992) | 0.009 | 0.186 | 0.081 |
Diastolic BP (mmHg) | 0.958 (0.922-0.996) | 0.030 | 0.126 | 0.553 |
Urea (mmol/l) | 1.546 (1.167-2.048) | 0.002 | 0.296 | 0.616 |
Creatinine (μmol/l) | 1.034 (1.008-1.061) | 0.010 | 0.264 | 0.004 |
Creatinine clearance (ml/min) | 0.954 (0.927-0.982) | 0.001 | 0.305 | 0.220 |
Cholesterol (mmol/l) | 0.677 (0.432-1.062) | 0.090 | 0.074 | 0.464 |
LDL (mmol/l) | 0.591 (0.349-1.000) | 0.050 | 0.100 | 0.672 |
Pro-BNP (pg/ml) | 1.000 (1.000-1.001) | 0.022 | 0.176 | 0.549 |
Glycaemia (mmol/l) | 1.270 (1.043-1.547) | 0.017 | 0.172 | 0.109 |
RBC count (x1012/l) | 0.227 (0.070-0.739) | 0.014 | 0.167 | 0.913 |
Haemoglobin (g/l) | 0.914 (0.869-0.961) | <0.001 | 0.439 | 0.382 |
Furosemide | 4.000 (1.198-13.357) | 0.024 | 0.122 | 0.516 |
Multivariateanalysis | OR (95%CI) | p-value | R2 | HL test p-value |
Gal-3 level at aortic roota | 1.228 (1.011-1.491) | 0.038 | 0.621 | 0.440 |
Haemoglobin (g/l) | 0.821 (0.699-0.965) | 0.017 | 0.621 | 0.440 |
Gal-3 level Femoral/radial arterya | 3.438 (1.275-9.265) | 0.015 | 0.846 | 0.943 |
Haemoglobin (g/l) | 0.860 (0.765-0.966) | 0.011 | 0.846 | 0.943 |
Creatinine clearance (ml/min) | 0.908 (0.829-0.994) | 0.036 | 0.846 | 0.943 |
Gal-3 level coronary sinusa | 1.044 (0.663-1.644) | 0.851 | 0.519 | 0.858 |
Haemoglobin (g/l) | 0.927 (0.874-0.984) | 0.012 | 0.519 | 0.858 |
Gal-3 level cubital veina | 1.163 (0.694-1.948) | 0.566 | 0.519 | 0.860 |
Haemoglobin (g/l) | 0.927 (0.874-0.984) | 0.012 | 0.519 | 0.860 |
Urea (mmol/l) | 1.521 (1.039-2.226) | 0.031 | 0.519 | 0.860 |
Gal-3 at site | AUC (95% CI) | SE | p-value | Cut-off (ng/ml) | Sn (%) | Sp (%) | PPV (%) | NPV (%) |
---|---|---|---|---|---|---|---|---|
Aortic root | 0.858 (0.744-0.973) | 0.058 | <0.001 | 10.86 | 80% | 87% | 76% | 89% |
Femoral artery | 0.742 (0.596-0.888) | 0.074 | 0.006 | 10.18 | 70% | 77% | 61% | 83% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
Submitted:
21 September 2023
Posted:
25 September 2023
You are already at the latest version
A peer-reviewed article of this preprint also exists.
Submitted:
21 September 2023
Posted:
25 September 2023
You are already at the latest version
All patientsN = 59 | No MACE or deathN = 39 | MACE or deathN = 20 | p-value | |
---|---|---|---|---|
Galectin-3 at site: | ||||
Aortic root (Q1, Q3), ng/ml | 9.2 (6.8-12.1) | 8.2 (5.9-9.9) | 13.9 (10.8-16.2) | <0.001 |
Femoral/radial artery + SD, ng/ml | 9.72 ± 3.62 | 8.53 ± 3.46 | 11.55 ± 3.15 | 0.005 |
Coronary sinus + SD, ng/ml | 9.74 ± 3.76 | 8.43 ± 2.57 | 12.56 ± 4.40 | 0.001 |
Cubital vein + SD, ng/ml | 9.31 ± 3.35 | 8.05 ± 2.21 | 12.06 ± 3.80 | <0.001 |
Age + SD, years | 65 ± 9 | 63 ± 8 | 69 ± 10 | 0.013 |
Gender (male), n (%) | 42 (71) | 32 (78.0%) | 9 (50.0%) | 0.063 |
BMI + SD, kg/m2 | 27.8 + 3.52 | 27.8 ± 3.4 | 27.8 ± 3.9 | 0.960 |
Smoking, n (%) | 18 (31) | 14 (34) | 4 (22) | 0.540 |
Diabetes mellitus, n (%) | 20 (34) | 14 (70) | 6 (30) | 0.999 |
CVI, n (%) | 3 (5) | 2 (5) | 1 (6) | 0.999 |
Hypertension, n (%) | 38 (64) | 24 (58) | 14 (78) | 0.238 |
Hyperlipoproteinemia, n (%) | 17 (29) | 11 (27) | 6 (33) | 0.756 |
STEMI, n (%) | 38 (64) | 23 (56) | 15 (83) | 0.044 |
Anterior MI, n (%) | 26 (44) | 16 (41) | 10 (50) | 0.239 |
Inferior MI, n (%) | 33 (56) | 23 (59) | 10 (50) | 0.969 |
NSTEMI, n (%) | 21 (36) | 16 (41) | 5 (25) | 0.044 |
Time from pain onset (Q1, Q3), hours | 10.0 (4.0-18.0) | 9.5 (4.0-20.0) | 8.5 (3.5-15.5) | 0.882 |
AV block, n (%) | 3 (5) | 0 (0) | 3 (17) | 0.025 |
VT/VF, n (%) | 7 (12) | 5 (12) | 2 (11) | 0.999 |
AF, n (%) | 5 (8) | 2 (5) | 3 (17) | 0.160 |
Systolic BP + SD, mmHg | 130 ± 28 | 137 ± 27 | 115 ± 26 | 0.005 |
Diastolic BP + SD, mmHg | 75 ± 17 | 79 ± 17 | 68 ± 15 | 0.023 |
HR + SD, bpm | 74 ± 14 | 76 ± 11 | 70 ± 21 | 0.272 |
Urea (Q1, Q3), mmol/l | 6.3 (4.9-8.5) | 5.8 (4.6-6.9) | 9.6 (7.4-13.3) | 0.003 |
Creatinine (Q1, Q3), μmol/l | 87.0 (78.0-100.0) | 86.0 (77.0-93.8) | 115.5 (79.8-167.8) | 0.044 |
Creatinine clearance + SD, ml/min | 83.41 ± 27.17 | 91.79 ± 21.29 | 64.32 ± 29.95 | <0.001 |
Cholesterol + SD, mmol/l | 5.68 ± 1.32 | 5.88 ± 1.19 | 5.22 ± 1.51 | 0.081 |
HDL + SD, mmol/l | 1.13 ± 0.26 | 1.12 ± 0.21 | 1.15 ± 0.35 | 0.742 |
LDL + SD, mmol/l | 3.66 ± 1.15 | 3.86 ± 1.02 | 3.19 ± 1.33 | 0.042 |
Triglycerides (Q1, Q3), mmol/l | 1.7 (1.1-2.3)) | 1.7 (1.2-2.5) | 1.3 (1.0-2.0) | 0.303 |
CK-MB (Q1, Q3), U/l | 24.0 (15.0-52.0) | 24.0 (16.2-54.0) | 25.0 (12.2-35.8) | 0.987 |
CRP (Q1, Q3), mg/l | 5.0 (1.5-10.6) | 4.2 (1.2-10.1) | 5.2 (2.7-33.0) | 0.278 |
Troponin T (Q1, Q3), ng/ml | 1.2 (0.2-7.3) | 1.1 (0.3-5.8) | 2.6 (0.1-5.2) | 0.593 |
Pro-BNP (Q1, Q3), pg/ml | 459.5 (239.7-2182.7) | 372.5 (180.2-1979.5) | 2250.0 (275.2-6492.8) | 0.004 |
Glycaemia (Q1, Q3), mmol/l | 6.2 (5.3-8.4) | 6.0 (5.3-7.0) | 8.2 (5.0-12.6) | 0.040 |
Potassium (Q1, Q3), mmol/l | 4.3 (4.0-4.6) | 4.2 (3.9-4.7) | 4.5 (4.1-4.7) | 0.281 |
Sodium (Q1, Q3), mmol/l | 139.0 (137.0-141.0) | 139.0 (137.2-141.0) | 139.5 (136.0-141.2) | 0.680 |
RBC + SD, x1012/l | 4.61 ± 0.56 | 4.73 ± 0.51 | 4.30 ± 0.58 | 0.007 |
Haemoglobin + SD, g/l | 137.43 ± 18.99 | 144.44 ± 14.62 | 120.53 ± 17.91 | <0.001 |
Leukocyte count (Q1, Q3), x109/l | 9.6 (8.6-12.0) | 9.4 (8.4-11.6) | 10.1 (7.4-12.9) | 0.657 |
Platelet count + SD, x109/l | 238.03 ± 65.60 | 232.73 ± 55.37 | 250.822 ± 80.62 | 0.406 |
LVEF + SD, % | 52 ± 5 | 53 ± 5 | 50 ± 6 | 0.157 |
EDV + SD, mm | 77.62 ± 22.65 | 76.82 ± 21.73 | 79.53 ± 25.33 | 0.683 |
ESV + SD, mm | 38.25 ± 13.38 | 38.8 (10.2-45.8) | 38.0 (31.5-45.8) | 0.392 |
E/A ratio (Q1, Q3) | 0.7 (0.6-0.8) | 0.7 (0.6-0.8) | 0.7 (0.6-1.0) | 0.925 |
E/E` ratio (Q1, Q3) | 7.9 (6.6-10.0) | 7.8 (6.5-9.7) | 8.0 (6.6-12.2) | 0.263 |
LA + SD, mm | 37.72 ± 4.93 | 38.20 ± 4.95 | 36.59 ± 4.84 | 0.262 |
Number of coronary lesions + SD | 1.67 + 0.87 | 1.68 ± 0.82 | 1.65 ± 1.00 | 0.887 |
1-vessel CAD, n (%) | 11 (19) | 8 (21) | 3 (15) | 0.869 |
2-vessel CAD, n (%) | 20 (34) | 15 (38) | 5 (25) | 0.601 |
3-vessel CAD, n (%) | 28 (47) | 16 (41) | 12 (60) | 0.029 |
Furosemide, n (%) | 18 (31) | 9 (22) | 9 (53) | 0.030 |
Spironolactone, n (%) | 10 (17) | 5 (12) | 5 (29) | 0.139 |
ACE inhibitors, n (%) | 42 (71) | 32 (78) | 10 (59) | 0.197 |
Beta-blockers, n (%) | 43 (73) | 33 (80) | 10 (59) | 0.107 |
Calcium channel antagonists, n (%) | 7 (12) | 3 (7) | 4 (23) | 0.178 |
Amiodarone, n (%) | 13 (22) | 8 (19) | 5 (29) | 0.494 |
DAPT, n (%) | 53 (90) | 39 (95) | 14 (82) | 0.144 |
Ticagrelor, n (%) | 33 (56) | 26 (63) | 7 (41) | 0.151 |
Trimetazidine, n (%) | 25 (42) | 18 (44) | 7 (41) | 0.999 |
Statins, n (%) | 54 (92) | 39 (95) | 15 (88) | 0.573 |
UFH/LMWH, n (%) | 55 (93) | 40 (98) | 15 (94) | 0.999 |
Event | n (%) |
---|---|
MACE, n (%) | 20 (100) |
Death, n (%) | 5 (25) |
Re-AMI, n (%) | 1 (5) |
Cerebrovascular insult, n (%) | 4 (20) |
Re-hospitalization due to heart failure, n (%) | 5 (25) |
Re-hospitalization due to malignant arrhythmias, n (%) | 5 (25) |
Univariate analysis | OR (95%CI) | p-value | R2 | HL test p-value |
---|---|---|---|---|
Galectin-3 at site: | ||||
Aortic root | 1.277 (1.076-1.517) | 0.005 | 0.255 | 0.581 |
Femoral/radial artery | 1.309 (1.068-1.604) | 0.009 | 0.224 | 0.556 |
Coronary sinus | 1.422 (1.155-1.750) | 0.001 | 0.342 | 0.48695 |
Cubital vein | 1.566 (1.225-2.000) | <0.001 | 0.405 | 0.454 |
Age (years) | 1.089 (1.014-1.169) | 0.018 | 0.145 | 0.289 |
Gender (male) | 0.281 (0.086-0.918) | 0.036 | 0.103 | 0.301 |
STEMI | 3.913 (0.980-15.625) | 0.053 | 0.101 | 0.300 |
NSTEMI | 0.256 (0.064-1.020) | 0.053 | 0.101 | 0.300 |
3-vessel CAD, n (%) | 3.375 (1.110-12.669) | 0.033 | 0.115 | 0.256 |
Systolic BP (mmHg) | 0.968 (0.945-0.992) | 0.009 | 0.186 | 0.081 |
Diastolic BP (mmHg) | 0.958 (0.922-0.996) | 0.030 | 0.126 | 0.553 |
Urea (mmol/l) | 1.546 (1.167-2.048) | 0.002 | 0.296 | 0.616 |
Creatinine (μmol/l) | 1.034 (1.008-1.061) | 0.010 | 0.264 | 0.004 |
Creatinine clearance (ml/min) | 0.954 (0.927-0.982) | 0.001 | 0.305 | 0.220 |
Cholesterol (mmol/l) | 0.677 (0.432-1.062) | 0.090 | 0.074 | 0.464 |
LDL (mmol/l) | 0.591 (0.349-1.000) | 0.050 | 0.100 | 0.672 |
Pro-BNP (pg/ml) | 1.000 (1.000-1.001) | 0.022 | 0.176 | 0.549 |
Glycaemia (mmol/l) | 1.270 (1.043-1.547) | 0.017 | 0.172 | 0.109 |
RBC count (x1012/l) | 0.227 (0.070-0.739) | 0.014 | 0.167 | 0.913 |
Haemoglobin (g/l) | 0.914 (0.869-0.961) | <0.001 | 0.439 | 0.382 |
Furosemide | 4.000 (1.198-13.357) | 0.024 | 0.122 | 0.516 |
Multivariateanalysis | OR (95%CI) | p-value | R2 | HL test p-value |
Gal-3 level at aortic roota | 1.228 (1.011-1.491) | 0.038 | 0.621 | 0.440 |
Haemoglobin (g/l) | 0.821 (0.699-0.965) | 0.017 | 0.621 | 0.440 |
Gal-3 level Femoral/radial arterya | 3.438 (1.275-9.265) | 0.015 | 0.846 | 0.943 |
Haemoglobin (g/l) | 0.860 (0.765-0.966) | 0.011 | 0.846 | 0.943 |
Creatinine clearance (ml/min) | 0.908 (0.829-0.994) | 0.036 | 0.846 | 0.943 |
Gal-3 level coronary sinusa | 1.044 (0.663-1.644) | 0.851 | 0.519 | 0.858 |
Haemoglobin (g/l) | 0.927 (0.874-0.984) | 0.012 | 0.519 | 0.858 |
Gal-3 level cubital veina | 1.163 (0.694-1.948) | 0.566 | 0.519 | 0.860 |
Haemoglobin (g/l) | 0.927 (0.874-0.984) | 0.012 | 0.519 | 0.860 |
Urea (mmol/l) | 1.521 (1.039-2.226) | 0.031 | 0.519 | 0.860 |
Gal-3 at site | AUC (95% CI) | SE | p-value | Cut-off (ng/ml) | Sn (%) | Sp (%) | PPV (%) | NPV (%) |
---|---|---|---|---|---|---|---|---|
Aortic root | 0.858 (0.744-0.973) | 0.058 | <0.001 | 10.86 | 80% | 87% | 76% | 89% |
Femoral artery | 0.742 (0.596-0.888) | 0.074 | 0.006 | 10.18 | 70% | 77% | 61% | 83% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
Beata Bobrowska
et al.
IJMS,
2017
Giulia Gagno
et al.
JCM,
2019
© 2024 MDPI (Basel, Switzerland) unless otherwise stated